Header Logo

Connection

NICOLA HANANIA to Disease Progression

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Disease Progression.
NICOLA HANANIA
Connection Strength
1.617
Disease Progression
  1. Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respir Med. 2025 01; 236:107846.
    View in: PubMed
    Score: 0.142
  2. Revisiting the Use of Antibiotics to Prevent COPD Exacerbation: Is Doxycycline the Answer? Am J Respir Crit Care Med. 2023 09 01; 208(5):509-511.
    View in: PubMed
    Score: 0.131
  3. Revisiting Mild Asthma: Current Knowledge and Future Needs. Chest. 2022 01; 161(1):26-39.
    View in: PubMed
    Score: 0.114
  4. Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps. Curr Opin Pulm Med. 2021 01; 27(1):45-53.
    View in: PubMed
    Score: 0.109
  5. Immunological biomarkers in severe asthma. Semin Immunol. 2019 12; 46:101332.
    View in: PubMed
    Score: 0.101
  6. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:117-127.
    View in: PubMed
    Score: 0.095
  7. Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. J Am Med Dir Assoc. 2017 Dec 01; 18(12):1063-1068.
    View in: PubMed
    Score: 0.088
  8. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD. 2017 Oct; 14(5):552-563.
    View in: PubMed
    Score: 0.086
  9. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. J Am Med Dir Assoc. 2017 Nov 01; 18(11):955-959.e6.
    View in: PubMed
    Score: 0.086
  10. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 10; 4(10):781-796.
    View in: PubMed
    Score: 0.081
  11. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):804-11.
    View in: PubMed
    Score: 0.064
  12. A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest. 2011 Sep; 140(3):565-566.
    View in: PubMed
    Score: 0.057
  13. Asthma in older adults. Clin Chest Med. 2007 Dec; 28(4):685-702, v.
    View in: PubMed
    Score: 0.044
  14. Frailty associates with respiratory exacerbations and mortality in the COPDGene cohort. Aging (Albany NY). 2025 Jul 03; 17(7):1590-1623.
    View in: PubMed
    Score: 0.037
  15. A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease. JAMA. 2025 06 24; 333(24):2164-2175.
    View in: PubMed
    Score: 0.037
  16. Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores. Respir Med. 2025 May; 241:108015.
    View in: PubMed
    Score: 0.036
  17. Promoting Prevention and Targeting Remission of Asthma: A EUFOREA Consensus Statement on Raising the Bar in Asthma Care. Chest. 2025 Apr; 167(4):956-974.
    View in: PubMed
    Score: 0.036
  18. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
    View in: PubMed
    Score: 0.034
  19. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 06 27; 390(24):2274-2283.
    View in: PubMed
    Score: 0.034
  20. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022 08; 162(2):297-308.
    View in: PubMed
    Score: 0.030
  21. Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.
    View in: PubMed
    Score: 0.027
  22. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 02 01; 195(3):324-330.
    View in: PubMed
    Score: 0.021
  23. Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016 07; 13(7):1016-25.
    View in: PubMed
    Score: 0.020
  24. Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. Chest. 2016 Apr; 149(4):916-26.
    View in: PubMed
    Score: 0.019
  25. Antifungals in severe asthma. Curr Opin Pulm Med. 2015 Jan; 21(1):48-54.
    View in: PubMed
    Score: 0.018
  26. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec; 132(6):1295-302.
    View in: PubMed
    Score: 0.016
  27. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
    View in: PubMed
    Score: 0.016
  28. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011 Jul; 107(1):65-70.
    View in: PubMed
    Score: 0.014
  29. Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). Prim Care Respir J. 2009 Sep; 18(3):198-207.
    View in: PubMed
    Score: 0.012
  30. It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.